Cracks in rubber under tension exceed the shear wave speed

The shear wave speed is an upper limit for the speed of cracks loaded in tension in linear elastic solids. We have discovered that in a non-linear material, cracks in tension (Mode I) exceed this sound speed, and travel in an intersonic range between shear and longitudinal wave speeds. The experiments are conducted in highly stretched sheets of rubber; intersonic cracks can be produced simply by popping a balloon.Comment: 4 pages, 5 eps figure

Book Reviews

Reviews of the following books: A Maritime History of Bath, Maine and the Kennebec Region by William A. Baker; Maine Made Guns and Their Makers by Dwight B. Demeritt, Jr

Capacity Investment Timing by Start-ups and Established Firms in New Markets

We analyze the competitive capacity investment timing decisions of both established firms and start-ups entering new markets, which have a high degree of demand uncertainty. Firms may invest in capacity early (when uncertainty is high) or late (when uncertainty has been resolved), possibly at different costs. Established firms choose an investment timing and capacity level to maximize expected profits, whereas start-ups make those choices to maximize the probability of survival. When a start-up competes against an established firm, we find that when demand uncertainty is high and costs do not decline too severely over time, the start-up takes a leadership role and invests first in capacity, whereas the established firm follows; by contrast, when two established firms compete in an otherwise identical game, both firms invest late. We conclude that the threat of firm failure significantly impacts the dynamics of competition involving start-ups

Persistent holes in a fluid

We observe stable holes in a vertically oscillated 0.5 cm deep aqueous suspension of cornstarch for accelerations a above 10g. Holes appear only if a finite perturbation is applied to the layer. Holes are circular and approximately 0.5 cm wide, and can persist for more than 10^5 cycles. Above a = 17g the rim of the hole becomes unstable producing finger-like protrusions or hole division. At higher acceleration, the hole delocalizes, growing to cover the entire surface with erratic undulations. We find similar behavior in an aqueous suspension of glass microspheres.Comment: 4 pages, 6 figure

Oscillating Fracture in Rubber

We have found an oscillating instability of fast-running cracks in thin rubber sheets. A well-defined transition from straight to oscillating cracks occurs as the amount of biaxial strain increases. Measurements of the amplitude and wavelength of the oscillation near the onset of this instability indicate that the instability is a Hopf bifurcation

A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease

Background: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenetic disorders in humans and is characterized by numerous fluid-filled cysts that grow slowly, resulting in end-stage renal disease in the majority of patients. Preclinical studies have indicated that treatment with low-dose thiazolidinediones, such as pioglitazone, decrease cyst growth in rodent models of PKD. Methods: This Phase 1b cross-over study compared the safety of treatment with a low dose (15 mg) of the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist pioglitazone or placebo in PKD patients, with each treatment given for 1 year. The study monitored known side effects of PPAR-γ agonist treatment, including fluid retention and edema. Liver enzymes and risk of hypoglycemia were assessed throughout the study. As a secondary objective, the efficacy of low-dose pioglitazone was followed using a primary assessment of total kidney volume (TKV), blood pressure (BP) and kidney function. Results: Eighteen patients were randomized and 15 completed both arms. Compared with placebo, allocation to pioglitazone resulted in a significant decrease in total body water as assessed by bioimpedance analysis {mean difference 0.16 Ω [95% confidence interval (CI) 0.24-2.96], P = 0.024} and no differences in episodes of heart failure, clinical edema or change in echocardiography. Allocation to pioglitazone led to no difference in the percent change in TKV of -3.5% (95% CI -8.4-1.4, P = 0.14), diastolic BP and microalbumin:creatinine ratio. Conclusions: In this small pilot trial in people with ADPKD but without diabetes, pioglitazone 15 mg was found to be as safe as placebo. Larger and longer-term randomized trials powered to assess effects on TKV are needed

Time dependencies in the occurrences of epileptic seizures

A new method of analysis, developed within the framework of nonlinear dynamics, is applied to patient recorded time series of the occurrence of epileptic seizures. These data exhibit broad band spectra and generally have no obvious structure. The goal is to detect hidden internal dependencies in the data without making any restrictive assumptions, such as linearity, about the structure of the underlying system. The basis of our approach is a conditional probabilistic analysis in a phase space reconstructed from the original data. The data, recorded from patients with intractable epilepsy over a period of 1-3 years, consist of the times of occurrences of hundreds of partial complex seizures. Although the epileptic events appear to occur independently, we show that the epileptic process is not consistent with the rules of a homogeneous Poisson process or generally with a random (IID) process. More specifically, our analysis reveals dependencies of the occurrence of seizures on the occurrence of preceding seizures. These dependencies can be detected in the interseizure interval data sets as well as in the rate of seizures per time period. We modeled patient's inaccuracy in recording seizure events by the addition of uniform white noise and found that the detected dependencies are persistent after addition of noise with standard deviation as great as 1/3 of the standard deviation of the original data set. A linear autoregressive analysis fails to capture these dependencies or produces spurious ones in most of the cases.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/31879/1/0000830.pd

Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases

Age-associated neurodegenerative disorders such as Alzheimer’s disease are a major public health challenge, due to the demographic increase in the proportion of older individuals in society. However, the relatively few currently approved drugs for these conditions provide only symptomatic relief. A major goal of neurodegeneration research is therefore to identify potential new therapeutic compounds that can slow or even reverse disease progression, either by impacting directly on the neurodegenerative process or by activating endogenous physiological neuroprotective mechanisms that decline with ageing. This requires model systems that can recapitulate key features of human neurodegenerative diseases that are also amenable to compound screening approaches. Mammalian models are very powerful, but are prohibitively expensive for high-throughput drug screens. Given the highly conserved neurological pathways between mammals and invertebrates, Caenorhabditis elegans has emerged as a powerful tool for neuroprotective compound screening. Here we describe how C. elegans has been used to model various human ageing-associated neurodegenerative diseases and provide an extensive list of compounds that have therapeutic activity in these worm models and so may have translational potential

Drug discovery in ophthalmology: past success, present challenges, and future opportunities

BACKGROUND: Drug discovery has undergone major transformations in the last century, progressing from the recognition and refinement of natural products with therapeutic benefit, to the systematic screening of molecular libraries on whole organisms or cell lines and more recently to a more target-based approach driven by greater knowledge of the physiological and pathological pathways involved. Despite this evolution increasing challenges within the drug discovery industry are causing escalating rates of failure of development pipelines. DISCUSSION: We review the challenges facing the drug discovery industry, and discuss what attempts are being made to increase the productivity of drug development, including a refocusing on the study of the basic biology of the disease, and an embracing of the concept of ‘translational research’. We consider what ophthalmic drug discovery can learn from the sector in general and discuss strategies to overcome the present limitations. This includes advances in the understanding of the pathogenesis of disease; improvements in animal models of human disease; improvements in ophthalmic drug delivery and attempts at patient stratification within clinical trials. SUMMARY: As we look to the future, we argue that investment in ophthalmic drug development must continue to cover the whole translational spectrum (from ‘bench to bedside and back again’) with recognition that both biological discovery and clinical understanding will drive drug discovery, providing safe and effective therapies for ocular disease